Trials / Completed
CompletedNCT02776371
Modified Non-clarithromycin Triple Therapy in Eradicating Helicobacter Pylori
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 301 (actual)
- Sponsor
- Shandong University · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
Helicobacter pylori (H. pylori) infects more than 50% of the population in the world(1), especially 47-66% in China.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Modified non-clarithromycin triple therapy | H. pylori infected patients treated with 10 mg rabeprazole twice a day, and 1g amoxicillin, 500 mg tinidazole three times a day for 14 days. |
| DRUG | Sequential therapy | H. pylori infected patients treated with 10 mg rabeprazole and 1 g amoxicillin, twice daily for 7 days, followed by 10 mg rabeprazole, 500 mg clarithromycin, and 500 mg tinidazole, twice daily for the next 7 days. |
Timeline
- Start date
- 2016-09-01
- Primary completion
- 2018-01-01
- Completion
- 2018-02-01
- First posted
- 2016-05-18
- Last updated
- 2018-12-24
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02776371. Inclusion in this directory is not an endorsement.